ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of gastric cancer

被引：38

作者：

Cunningham, D

Jost, LM

Purkalne, G

Oliveira, J

机构：

[1] Royal Marsden Hosp, Sutton SM2 5PT, Surrey, England

[2] Kantonsspital, CH-4101 Bruderholz BL, Switzerland

[3] P Stradins Univ Hosp, Radiat & Chemotherapy Ctr, LV-1002 Riga, Latvia

[4] Inst Portugues Oncol Francisco Gentil, P-1099023 Lisbon, Portugal

来源：

ANNALS OF ONCOLOGY | 2005年 / 16卷

关键词：

D O I：

10.1093/annonc/mdi812

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：22 / 23

页数：2

共 10 条

[1] A systematic overview of chemotherapy effects in gastric cancer [J].

Janunger, KG ;

Hafström, L ;

Nygren, P ;

Glimelius, B .

ACTA ONCOLOGICA, 2001, 40 (2-3) :309-326

[2]

Jordan Karin, 2004, Clin Colorectal Cancer, V4, P46, DOI 10.3816/CCC.2004.n.009

[3] Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. [J].

Macdonald, JS ;

Smalley, SR ;

Benedetti, J ;

Hundahl, SA ;

Estes, NC ;

Stemmermann, GN ;

Haller, DG ;

Ajani, JA ;

Gunderson, LL ;

Jessup, JM ;

Martenson, JA .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (10) :725-730

[4] Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: A meta-analysis of published randomised trials - A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) [J].

Mari, E ;

Floriani, I ;

Tinazzi, A ;

Buda, A ;

Belfiglio, M ;

Valentini, M ;

Cascinu, S ;

Barni, S ;

Labianca, R ;

Torri, V .

ANNALS OF ONCOLOGY, 2000, 11 (07) :837-843

[5] 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere®)-cisplatin in advanced gastric carcinoma:: a phase I-II trial [J].

Roth, AD ;

Maibach, R ;

Fazio, N ;

Sessa, C ;

Stupp, R ;

Morant, R ;

Herrmann, R ;

Borner, MM ;

Goldhirsch, A ;

de Braud, F .

ANNALS OF ONCOLOGY, 2004, 15 (05) :759-764

[6] Current status and future perspectives in gastric cancer management [J].

Roukos, DH .

CANCER TREATMENT REVIEWS, 2000, 26 (04) :243-255

[7]

Schuhmacher CP, 2001, CANCER-AM CANCER SOC, V91, P918, DOI 10.1002/1097-0142(20010301)91:5<918::AID-CNCR1081>3.0.CO

[8]

2-W

[9] Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial [J].

Souglakos, J ;

Syrigos, K ;

Potamianou, A ;

Polyzos, A ;

Boukovinas, I ;

Androulakis, N ;

Kouroussis, C ;

Vardakis, N ;

Christophilakis, C ;

Kotsakis, A ;

Georgoulias, V .

ANNALS OF ONCOLOGY, 2004, 15 (08) :1204-1209

[10] Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer [J].

Webb, A ;

Cunningham, D ;

Scarffe, JH ;

Harper, P ;

Norman, A ;

Joffe, JK ;

Hughes, M ;

Mansi, J ;

Findlay, M ;

Hill, A ;

Oates, J ;

Nicolson, M ;

Hickish, T ;

OBrien, M ;

Iveson, T ;

Watson, M ;

Underhill, C ;

Wardley, A ;

Meehan, M .

JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :261-267

← 1 →